http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2566684-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e18c7e548ce14832e87e11832c19dd9
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-409
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4415
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-409
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
filingDate 2005-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_562b168d485ec783e4dfc1275ff8e438
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4a7c5b55d454b6e05e2ce14c0cc2154
publicationDate 2005-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2566684-A1
titleOfInvention Pharmaceutical nitrones
abstract Pharmaceutical nitrone comprise condensates of an N-hydroxylamine and a physiological aldehyde, providing improved delivery and absorption, enhanced stability and reduced toxicity. Preferred physiological aldehydes are subject to endogenous cellular uptake transport, and include pyridoxal, pyridoxal phosphate, and heme-A. Essentially any physiologically compatible and pharmaceutically active hydroxylamine moiety may be incorporated, such as hydroxylamine moieties of prior pharmaceutical nitrones, and known pharmaceutically active hydroxylamines.
priorityDate 2004-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412215776
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1050
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID787
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556436
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21023799
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474140
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1051
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6350
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419526450
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426383914

Total number of triples: 40.